The Utility of activated Partial Thromboplastin Time (aPTT) Clot Waveform Analysis in the Investigation of Hemophilia A Patients with very Low Levels of Factor VIII Activity (FVIII:C)

Summary

The lower detection limit of the conventional one-stage aPTT based clotting assay for determining FVIII:C levels is generally 1.0-2.0 IU/dl. Consequently, it has been impossible to study the clinical significance of levels of FVIII:C less than 1.0 IU/dl. Using a photo-optical automated coagulation analyzer, the Organon Teknika MDA II®, we have performed qualitative and quantitative aPTT waveform analysis and measured FVIII:C levels by automated one-stage aPTT clotting assay in 36 severely affected Hemophilia A patients. Qualitative waveform analysis showed clear evidence of individual differences in the waveform profile suggesting differing coagulant activity from patient to patient. The FVIII:C level was less than 0.2 IU/dl in 23 cases and levels of FVIII:C between 0.2 and 1.0 IU/dl could be discriminated in 13 patients. The FVIII:C level in these patients was closely correlated with the minimum value of the second derivative of the aPTT waveform (Min2). This is a measure of the acceleration of change in optical transmission at the initiation of coagulation. Furthermore, the correlation of the aPTT (time and Min2) and the FVIII:C level, determined by a one-stage clotting assay on the same system, was high in plasmas with a range of levels of FVIII:C artificially prepared by the addition of various concentrations of rFVIII:C to FVIII deficient plasma. These data suggest that it is possible to segregate different levels of clotting activity in patients previously assigned to a single grouping, i.e. less than 1.0 IU/dl, by conventional one-stage assay. Thus clot waveform analysis may be useful for the investigation of the clinical phenotype of individual patients and their response to therapy.

Keywords

Factor VIII (FVIII) - factor VIII activity (FVIII:C) - waveform analysis

• References

• 1 Brinkhaus KM, Graham JB. Hemophilia and hemophilic states. Blood 1954; 09: 254-7.
• 2 Hardisty RM, Macpherson JC. A one-stage factor VIII (antihaemophilic globulin) assay and its use on venous and capillary plasma. Thrombos Diathes Haemorrh 1962; 07: 215-28.
• 3 Rosen S, Andersson M, Blombäck M, Hagglund U, Larrieu MJ, Wolf M, Boyer C, Rothschild C, Nilsson IM, Sjorin E, Vinazzer H. Clinical application of a chromogenic substrate method for determination of factor VIII activity. Thromb Haemost 1985; 54: 818-23.
• 4 Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chew AJ, Tai SJ, Herzog RW, Arruda V, Johnson F, Scallan C, Skarsgard E, Flake AW, High KA. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with AAV vector. Nat Genet 2000; 24: 257-61.
• 5 Braun PJ, Givens TB, Stead AG, Beck LR, Gooch SA, Swan RJ, Fischer TJ. Properties of optical data from activated partial thromboplastin time and prothrombin time assays. Thromb Haemost 1997; 78: 1079-87.
• 6 Kamisue S, Shima M, Nishimura T, Tanaka I, Nakai H, Morichika S, Takata N, Kuramoto A, Yoshioka A. Abnormal factor VIII Hiroshima:defect in crucial proteolytic cleavage by thrombin at Arg1689 detected by a novel ELISA. Br J Haematol 1994; 86: 106-11.
• 7 Peason K, Lee A. On the laws of inheritance in man. Biometrika 1902; 02: 357-97.